Srinivas M Ammisetty, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9350 Us Hwy 23 South, Suite 104, Stanville, KY 41659 Phone: 606-478-1005 Fax: 606-478-8687 |
News Archive
MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.
A recently published CDC report is helping uncover the characteristics of homicides of American Indian and Alaska Native (AI/AN) people.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.
Natural Killer (NK) cells, lymphocytes of the innate immune system with strong cytotoxic activity, play a major role in the immune response against tumors.
› Verified 3 days ago